Relmada Therapeutics updates corporate presentation on CNS pipeline

RELMADA THERAPEUTICS, INC.

Filed corporate presentation dated October 10, 2023 as Exhibit 99.1.
No specific financial or clinical data disclosed in the 8-K filing.
Presentation title: 'Targeting Major Advances in the Treatment of CNS Disorders'.

item 8.01 item 9.01

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001013762-23-002900

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.